We are live on
!
Find out more
SCP
Shorepoint Capital Partners Portfolio holdings
AUM
$503M
This Fund
S&P 500
This Quarter
Est. Return
+2.96%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$175M
AUM Growth
-$1.38M
(-0.78%)
Cap. Flow
-$5.75M
Cap. Flow
% of AUM
-3.28%
Top 10 Holdings %
Top 10 Hldgs %
31.53%
Holding
90
New
4
Increased
17
Reduced
60
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHI
Calamos Convertible Opportunities and Income Fund
CHI
|
+$831K |
| 2 |
EFT
Eaton Vance Floating-Rate Income Trust
EFT
|
+$812K |
| 3 |
Occidental Petroleum
OXY
|
+$716K |
| 4 |
Alcon
ALC
|
+$707K |
| 5 |
Tapestry
TPR
|
+$545K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ameriprise Financial
AMP
|
+$949K |
| 2 |
Apple
AAPL
|
+$777K |
| 3 |
Teva Pharmaceuticals
TEVA
|
+$772K |
| 4 |
Kraft Heinz
KHC
|
+$634K |
| 5 |
VF Corp
VFC
|
+$503K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.41% |
| 2 | Financials | 11.09% |
| 3 | Technology | 10.86% |
| 4 | Industrials | 8.15% |
| 5 | Consumer Discretionary | 8.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Novartis
NVS
$303B
| $2.5M | 1.42% |
27,333
-2,445
| -8% | -$207K |
|
27
Invesco Preferred ETF
PGX
$3.81B
| $2.49M | 1.42% |
170,417
+13,729
| +9% | +$200K |
|
28
Schwab US Mid-Cap ETF
SCHM
$14.5B
| $2.44M | 1.39% |
128,463
-11,328
| -8% | -$212K |
|
29
Old Republic International
ORI
$10.7B
| $2.44M | 1.39% |
109,145
-1,530
| -1% | -$33.7K |
|
30
State Street SPDR S&P Dividend ETF
SDY
$22.3B
| $2.38M | 1.36% |
23,589
-424
| -2% | -$42.4K |
|
31
US Bancorp
USB
$99.6B
| $2.38M | 1.35% |
45,320
-735
| -2% | -$37.9K |
|
32
Trane Technologies
TT
$103B
| $2.35M | 1.34% |
18,523
-2,938
| -14% | -$351K |
|
33
MetLife
MET
$62.6B
| $2.21M | 1.26% |
44,507
-875
| -2% | -$41.1K |
|
|
34
Kraft Heinz
KHC
$32B
| $2.15M | 1.23% |
69,324
-20,098
| -22% | -$634K |
|
35
Eaton
ETN
$149B
| $2.13M | 1.21% |
25,574
-440
| -2% | -$35.6K |
|
36
Kinder Morgan
KMI
$70.7B
| $2.11M | 1.2% |
100,902
+925
| +0.9% | +$18.7K |
|
37
Unilever
UL
$143B
| $2.07M | 1.18% |
29,629
-3,290
| -10% | -$223K |
|
|
PPL
38
PPL Corp
PPL
$27.3B
| $2.02M | 1.15% |
65,305
-5,894
| -8% | -$183K |
|
39
Dominion Energy
D
$62.4B
| $2.02M | 1.15% |
26,130
-475
| -2% | -$36.2K |
|
40
Johnson Controls International
JCI
$84.6B
| $2.02M | 1.15% |
48,848
-1,338
| -3% | -$51.5K |
|
41
iShares Preferred and Income Securities ETF
PFF
$13.2B
| $1.89M | 1.08% |
51,401
-3,375
| -6% | -$124K |
|
42
HSBC
HSBC
$355B
| $1.81M | 1.03% |
43,432
-4,762
| -10% | -$199K |
|
43
Simon Property Group
SPG
$76.9B
| $1.74M | 0.99% |
10,886
-972
| -8% | -$167K |
|
44
Bank of America
BAC
$438B
| $1.65M | 0.94% |
56,725
-2,402
| -4% | -$69.3K |
|
45
Alphabet (Google) Class A
GOOGL
$4.1T
| $1.58M | 0.9% |
29,280
-2,360
| -7% | -$137K |
|
46
Thermo Fisher Scientific
TMO
$212B
| $1.57M | 0.9% |
5,360
-765
| -12% | -$211K |
|
47
Visa
V
$702B
| $1.53M | 0.88% |
8,844
-756
| -8% | -$124K |
|
48
Medtronic
MDT
$111B
| $1.5M | 0.86% |
15,408
+1,730
| +13% | +$158K |
|
49
iShares S&P 500 Growth ETF
IVW
$72.1B
| $1.5M | 0.85% |
33,388
-1,136
| -3% | -$50K |
|
|
50
Tapestry
TPR
$30.3B
| $1.35M | 0.77% |
42,480
+17,490
| +70% | +$545K |
|
Similar funds
VBFG
JWM
FNC
OHWA
ODG
GP
SCA
SFPM
Shorepoint Capital Partners's Q2 2019 Portfolio in Review
As of Q2 2019, Shorepoint Capital Partners held 90 positions worth $175M, down 0.78% from $177M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Shorepoint Capital Partners withdrew a net $5.75M in Q2 2019, closing 3 positions and reducing 60 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $772K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 19% a quarter earlier, followed by Financials and Technology.
Against the trend, Shorepoint Capital Partners opened a new position in Calamos Convertible Opportunities and Income Fund worth $840K.
- Shorepoint Capital Partners's largest Q2 2019 buy was Calamos Convertible Opportunities and Income Fund: 80,000 shares worth $840K.
- Shorepoint Capital Partners added most to Occidental Petroleum in Q2 2019, an estimated $716K increase.
- Shorepoint Capital Partners's biggest Q2 2019 reduction was Ameriprise Financial, cutting an estimated $949K.
- Shorepoint Capital Partners fully exited Teva Pharmaceuticals in Q2 2019, selling an estimated $772K.
- Shorepoint Capital Partners's ten largest holdings make up 32% of its $175M portfolio in Q2 2019.
- Shorepoint Capital Partners opened 4 new positions and closed 3 in Q2 2019.
- Shorepoint Capital Partners's portfolio value fell 0.78% quarter-over-quarter to $175M.
Based on Shorepoint Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.